Article Details

Best choice between chemo or Braftovi/Erbitux in second-line rare colorectal cancer still debatable

Retrieved on: 2021-08-02 11:26:15

Tags for this article:

Click the tags to see associated articles and topics

Best choice between chemo or Braftovi/Erbitux in second-line rare colorectal cancer still debatable. View article details on hiswai:

Excerpt

The attraction behind BRAF inhibitors in 2L is the way they can target both cancer and immune system cells. Credits: crystal light/Shutterstock.com.

Article found on: www.clinicaltrialsarena.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up